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Background: There have been substantial improvements in the management of acute pancreatitis since
the publication of the International Association of Pancreatology (IAP) treatment guidelines in 2002. A
collaboration of the IAP and the American Pancreatic Association (APA) was undertaken to revise these
guidelines using an evidence-based approach.
Methods: Twelve multidisciplinary review groups performed systematic literature reviews to answer 38
predeﬁned clinical questions. Recommendations were graded using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) system. The review groups presented their recom-
mendations during the 2012 joint IAP/APA meeting. At this one-day, interactive conference, relevant
remarks were voiced and overall agreement on each recommendation was quantiﬁed using plenary
voting.
Results: The 38 recommendations covered 12 topics related to the clinical management of acute
pancreatitis: A) diagnosis of acute pancreatitis and etiology, B) prognostication/predicting severity, C)
imaging, D) ﬂuid therapy, E) intensive care management, F) preventing infectious complications, G)
nutritional support, H) biliary tract management, I) indications for intervention in necrotizing pancre-
atitis, J) timing of intervention in necrotizing pancreatitis, K) intervention strategies in necrotizing
pancreatitis, and L) timing of cholecystectomy. Using the GRADE system, 21 of the 38 (55%) recom-
mendations, were rated as ‘strong’ and plenary voting revealed ‘strong agreement’ for 34 (89%)
recommendations.
Conclusions: The 2012 IAP/APA guidelines provide recommendations concerning key aspects of medical
and surgical management of acute pancreatitis based on the currently available evidence. These rec-
ommendations should serve as a reference standard for current management and guide future clinical
research on acute pancreatitis.
Copyright  2013, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Acute pancreatitis is one of the most common gastrointestinal
disorders requiring acute hospitalization worldwide, with a re-
ported annual incidence of 13e45 cases per 100,000 persons [1]. In
the U.S. alone, acute pancreatitis leads to 270,000 hospital admis-
sions annually and inpatient costs exceed 2.5 billion dollars [2]. It is
clear that such a common disease associated with mortality up to
30% in severe cases, requires up-to-date evidence-based treatmentf Pancreatology, UNSW Clin-
871, Australia and American
N 55414, USA.
by Elsevier India, a division of Reeguidelines with broad support from the pancreatic community. A
recent systematic review has demonstrated the variable quality of
the 30 guidelines published since 1988 and has highlighted the
need for a high quality update [3]. Eleven years have passed since
the “Guidelines for the surgical management of acute pancreatitis” by
the International Association of Pancreatology (IAP) were pub-
lished in 2002 [4]. Since then, a large body of new evidence has
become available, not infrequently from randomized controlled
trials (RCTs) and systematic reviews. This evidence has greatly
inﬂuenced many important aspects of the medical and surgical
management of acute pancreatitis.
The leadership of both the IAP and the American Pancreatic
Association (APA) supported an initiative for an international
multidisciplinary approach to update the evidence-based guide-
lines for the management of acute pancreatitis. To this end and Elsevier India Pvt. Ltd. Open access under CC BY-NC-ND license.
Working Group IAP/APA Acute Pancreatitis Guidelines / Pancreatology 13 (2013) e1ee15e2adapted version of the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach [5] was used. Both
the revised Atlanta classiﬁcation for acute pancreatitis [6] and the
outcome of a recent consensus conference on interventions for
necrotizing pancreatitis [7] were taken into account. Systematic
reviews on 12 main topics answered 38 predeﬁned clinical ques-
tions which were presented and discussed during an interactive
symposium at the IAP/APA joint meeting in Miami on October 31,
2012.
2. Methods
2.1. Scope and purpose
The overall objective of these guidelines is to provide evidence-
based recommendations for the medical and surgical management
of patients with acute pancreatitis using clearly speciﬁed, clinically
relevant questions.
2.2. Stakeholder involvement
Individuals from all relevant professional groups involved with
acute pancreatitis were included. Target users of the guidelines are
all clinicians involved in the care of patients with acute pancreatitis.
2.3. General outline of the process
2.3.1. First phase: drafting of the working plan
The IAP/APA leadership actively supported an initiative (MGB,
HCvS, JW) to develop the current guidelines and invited seven clini-
cians to formthesteeringcommitteeandprovidedsecretarial support
(EB). Three coordinators (MGB, HCvS, JW) wrote the initial version of
the working plan and proposed the 12 main topics and associated
clinicalquestionsper topic andsuggestedthe reviewers foreachtopic.
This preliminary working plan was discussed via telephone confer-
ences and e-mailswithin the full steering committee and the IAP/APA
leadership, and then the document including the composition of re-
view groups was ﬁnalized. The IAP/APA leadership also invited nine
additional senior clinicians to form the executive committee in
addition to the members of the steering committee.
Each review group consisted of at least one primary reviewer
chosen because of recent publications on a particular topic and
several senior reviewers. An attempt was made to have multidis-
ciplinary input in each review group as well as representatives of at
least two continents. Each review group was also assigned a time
manager from the steering committee, whose primary task was to
ensure the completion of the review within the agreed timeframe.
The working plan for the review groups provided a structured
format for the systematic reviews. It included instructions on how
to grade the level of evidence and the strength of the recommen-
dations regarding clarity of risk/beneﬁt, quality of the supporting
evidence, and clinical implications according to the GRADE guide-
lines as adapted for ‘UpToDate’.
A group of ‘expert referees’ (see Collaborator section) was
identiﬁed based on relevant publications in the ﬁeld of clinical
acute pancreatitis and input during the IAP/APA meeting. This
group reviewed the guidelines in the ﬁnal stages. After a last round
of discussion within the executive committee, the working plan
was ﬁnalized to include 12 main topics and 38 clinical questions
concerning key aspects of medical and surgical management of
acute pancreatitis.
2.3.2. Second phase: Systematic literature reviews
The suggested reviewers were invited and given their respective
topics and clinical questions. All 12 review groups had theopportunity to suggest changes in clinical questions or suggest
additional questions to the steering committee. Over a ﬁve-month
period (JuneeOct 2012) the review groups performed systematic
reviews according to the guidelines deﬁned in the ﬁnalized work-
ing plan.
2.4. Systematic review guidelines
A systematic search for relevant articles was performed in the
PubMed, Embase, and Cochrane databases.
Inclusion criteria were: (1) randomized or observational cohort
studies, including systematic reviews, on patients with acute
pancreatitis focusing on the speciﬁc study questions with a sample
size of at least 20 patients, (2) studies published in English lan-
guage, and (3) available in full text. If review groups were capable of
translating non-English publications they were encouraged to do
so.
Exclusion criteria were: (1) non-randomized studies with less
than 20 patients because of the likelihood of selection bias, (2)
studies on patients with ‘acute on chronic pancreatitis’, and (3)
non-randomized studies prior to 1993 (i.e. publication of the initial
Atlanta classiﬁcation). RCTs prior to 1993 could only be excluded if
the reviewers felt that the generalizability to today’s practice was
not appropriate.
2.5. Grading of the evidence
All reviewers were asked to take a GRADE system tutorial (link
on UpToDate: http://www.uptodate.com/home/grading-tutorial).
2.6. Outcome reporting
The deﬁnitions of the revised Atlanta classiﬁcation for acute
pancreatitis were used [6].
The ﬁnal outcomes of the systematic reviews were discussed
amongst the members of the review group. The review groups
provided the following for each clinical question:
a. Recommendation: the GRADE strength of recommendation
(1 ¼ strong, 2 ¼ weak) and quality of evidence (A ¼ high,
B¼moderate, C¼ low) are provided along with the strength of
agreement during plenary voting (strong/weak) (see
Appendix). In the absence of studies speciﬁcally addressing the
question, this had to be stated and the recommendation was
then based on related studies or expert opinion.
b. Remarks: these remarks could discuss any relevant aspect
regarding the recommendation, such as important exceptions/
contra-indications, availability, lack of evidence, risks, and costs.
c. A summary table of relevant studies was produced, including
columns on outcome assessed (e.g. mortality, infected necro-
sis), the total number of patients, the number of included
studies per outcome, design of the study (e.g. retrospective
cohort, prospective cohort, RCT), and critical appraisal of
methodology according to the GRADE system for each study as
well as a summary of outcomes2.6.1. Third phase: IAP/APA joint meeting
The review groups (see Collaborator section) presented their
work at the IAP/APA Joint Annual Meeting on October 31st, 2012 in
Miami, Florida, USA using standardized PowerPoint templates. Each
clinical question was addressed in a similar manner in three slide
sections: (1) the question with the recommendation including the
GRADE score, (2) the remarks, and (3) a summary of the literature
studied. After each presentation, the 171 registered attendees (North
Working Group IAP/APA Acute Pancreatitis Guidelines / Pancreatology 13 (2013) e1ee15 e3America, n¼ 71; South America, n¼ 7; Europe, n¼ 54; Asia/Oceania,
n ¼ 39) were invited to comment. The general aim was not to alter
the recommendations, because these were based on systematic re-
views but rather to obtain clinically relevant comments to be added
to the ‘remarks’ section for that speciﬁc clinical question. Occasion-
ally, in case of absence of studies or unclear phrasing of the recom-
mendation, its’ wording was amended. In order to assess the level of
support from the international pancreatologists objectively, an
electronic plenary vote was conducted for each recommendation.
The attendees voted on a ﬁve point Likert scale (‘deﬁnitely yes’,
‘probably yes’, ‘no speciﬁc recommendation’, ‘probably no’, ‘deﬁ-
nitely no’) on the recommendation and their GRADE score. These
answers were projected to the audience immediately after each
round of voting. Before the meeting, it was deﬁned that ‘strong
agreement’would require at least 70% of votes to be either ‘deﬁnitely
yes’ or ‘probably yes’. For optimal transparency the meeting was
ﬁlmed and these ﬁlms are accessible via the APA ofﬁce.2.6.2. Fourth phase: drafting of the manuscript
Based on the recommendations with remarks and GRADE rating,
the voting results, and the remarks provided during the meeting, the
coordinators drafted a ﬁrst version of the guidelines. Although
several relevant ongoing multicenter RCTs were identiﬁed in the
reviews (i.e. through published study protocols), it was decided toTable 1
Summary of recommendations
A. Diagnosis of acute pancreatitis and etiology
1. The deﬁnition of acute pancreatitis is based on the fulﬁllment of ‘2 out of 3’ of the follo
>3x upper limit of normal) and/or imaging (CT, MRI, ultrasonography) criteria.(GRA
2. On admission, the etiology of acute pancreatitis should be determined using detailed
medication and drug intake, known hyperlipidemia, trauma, recent invasive proced
laboratory serum tests (i.e. liver enzymes, calcium, triglycerides), and imaging (i.e. r
3. In patients considered to have idiopathic acute pancreatitis, after negative routine w
the ﬁrst step to assess for occult microlithiasis, neoplasms and chronic pancreatitis. If
rare morphologic abnormalities. CT of the abdomen should be performed. If etiolog
genetic counseling (not necessarily genetic testing) should be considered.(GRADE 2
B. Prognostication/prediction of severity
4. Systemic inﬂammatory response syndrome (SIRS) is advised to predict severe acute
agreement)
5. During admission, a 3-dimension approach is advised to predict outcome of acute p
clinical risk stratiﬁcation (e.g. persistent SIRS) and monitoring response to initial th
agreement)
C. Imaging
6. The indication for initial CT assessment in acute pancreatitis can be: 1) diagnostic un
pancreatitis, or 3) failure to respond to conservative treatment or in the setting of clin
after onset of symptoms.(GRADE 1C, strong agreement)
7. Follow up CT or MR in acute pancreatitis is indicated when there is a lack of clinica
considered.(GRADE 1C, strong agreement)
8. It is recommended to performmultidetector CT with thin collimation and slice thickn
rate of 3mL/s, during the pancreatic and/or portal venous phase (i.e. 50e70 seconds
sufﬁcient. For MR, the recommendation is to perform axial FS-T2 and FS-T1 scannin
strong agreement)
D. Fluid therapy
9. Ringer’s lactate is recommended for initial ﬂuid resuscitation in acute pancreatitis.(
10a. Goal directed intravenous ﬂuid therapy with 5e10 ml/kg/h should be used initial
10b. The preferred approach to assessing the response to ﬂuid resuscitation should be ba
120/min, mean arterial pressure between 65-85 mmHg (8.7e11.3 kPa), and urinary
intrathoracic blood volume determination, and 3) biochemical targets of hematocri
E. Intensive care management
11. Patients diagnosed with acute pancreatitis and one or more of the parameters iden
Medicine (SCCM). Furthermore, patients with severe acute pancreatitis as deﬁned by
an intensive care setting.(GRADE 1C, strong agreement)
12. Management in, or referral to, a specialist center is necessary for patients with sev
endoscopic, or surgical intervention.(GRADE 1C, strong agreement)
13. A specialist center in the management of acute pancreatitis is deﬁned as a high vo
replacement therapy, and with daily (i.e. 7 days per week) access to interventional ra
expertise in managing necrotizing pancreatitis. Patients should be enrolled in prosp
possible.(GRADE 2C, weak agreement)
14. Early ﬂuid resuscitation within the ﬁrst 24 hours of admission for acute pancreatitis
strong agreement)only report published work. This draft was discussed with the
steering and executive committees, the review groups, and ﬁnally
the expert referees. The review groups were speciﬁcally asked to
judge whether the amended remarks section of their clinical ques-
tion(s) still reﬂected the current state of the literature. The ﬁnal
version was approved by the steering and executive committees.2.7. Future aspects
These guidelines will be updated by an IAP/APA committee
when these associations believe there is a need to do so [8], but no
longer than 10 years after publication of these guidelines.3. Results
The 12 main topics (AeL) are presented consecutively, incor-
porating 38 clinical questions (Q1eQ38) and their answers. See
table 1 for a summary of the recommendations. The GRADE
strength of recommendation (1 ¼ strong, 2 ¼ weak) and quality of
evidence (A¼ high, B¼moderate, C¼ low) are provided alongwith
the strength of agreement during plenary voting (strong/weak). For
each recommendation the remarks from the reviewers and at-
tendees at the meeting are listed.wing criteria: clinical (upper abdominal pain), laboratory (serum amylase or lipase
DE 1B, strong agreement)
personal (i.e. previous acute pancreatitis, known gallstone disease, alcohol intake,
ures such as ERCP) and family history of pancreatic disease, physical examination,
ight upper quadrant ultrasonography).(GRADE 1B, strong agreement)
ork-up for biliary etiology, endoscopic ultrasonography (EUS) is recommended as
EUS is negative, (secretin-stimulated) MRCP is advised as a second step to identify
y remains unidentiﬁed, especially after a second attack of idiopathic pancreatitis,
C, weak agreement)
pancreatitis at admission and persistent SIRS at 48 hours.(GRADE 2B, weak
ancreatitis combining host risk factors (e.g. age, co-morbidity, body mass index),
erapy (e.g. persistent SIRS, blood urea nitrogen, creatinine).(GRADE 2B, strong
certainty, 2) conﬁrmation of severity based on clinical predictors of severe acute
ical deterioration. Optimal timing for initial CT assessment is at least 72e96 hours
l improvement, clinical deterioration, or especially when invasive intervention is
ess (i.e. 5mm or less), 100e150 ml of non-ionic intra-venous contrast material at a
delay). During follow up only a portal venous phase (monophasic) is generally
g before and after intravenous gadolinium contrast administration.(GRADE 1C,
GRADE 1B, strong agreement)
ly until resuscitation goals (see Q10b) are reached.(GRADE 1B, weak agreement)
sed on one ormore of the following: 1) non-invasive clinical targets of heart rate<
output > 0.5e1ml/kg/h, 2) invasive clinical targets of stroke volume variation, and
t 35-44%.(GRADE 2B, weak agreement)
tiﬁed at admission as deﬁned by the guidelines of the Society of Critical Care
the revised Atlanta Classiﬁcation (i.e. persistent organ failure) should be treated in
ere acute pancreatitis and for those who may need interventional radiologic,
lume center with up-to-date intensive care facilities including options for organ
diology, interventional endoscopy with EUS and ERCP assistance as well as surgical
ective audits for quality control issues and into clinical trials whenever
is associated with decreased rates of persistent SIRS and organ failure.(GRADE 1C,
(continued on next page)
Table 1 (continued )
15. Abdominal compartment syndrome (ACS) is deﬁned as a sustained intra-abdominal pressure > 20 mmHg that is associated with new onset organ failure.(GRADE 2B,
strong agreement)
16. Medical treatment of ACS should target 1) hollow-viscera volume, 2) intra/extra vascular ﬂuid and 3) abdominal wall expansion. Invasive treatment should only be
used after multidisciplinary discussion in patients with a sustained intra-abdominal pressure>25mmHgwith new onset organ failure refractory tomedical therapy and
nasogastric/ rectal decompression. Invasive treatment options include percutaneous catheter drainage of ascites, midline laparostomy, bilateral subcostal laparostomy,
or subcutaneous linea alba fasciotomy. In case of surgical decompression, the retroperitoneal cavity and the omental bursa should be left intact to reduce the risk of
infecting peripancreatic and pancreatic necrosis.(GRADE 2C, strong agreement)
F. Preventing infectious complications
17. Intravenous antibiotic prophylaxis is not recommended for the prevention of infectious complications in acute pancreatitis.(GRADE 1B, strong agreement)
18. Selective gut decontamination has shown some beneﬁts in preventing infectious complications in acute pancreatitis, but further studies are needed.(GRADE 2B, weak
agreement)
19. Probiotic prophylaxis is not recommended for the prevention of infectious complications in acute pancreatitis.(GRADE 1B, strong agreement)
G. Nutritional support
20. Oral feeding in predictedmild pancreatitis can be restarted once abdominal pain is decreasing and inﬂammatorymarkers are improving.(GRADE 2B, strong agreement)
21. Enteral tube feeding should be the primary therapy in patients with predicted severe acute pancreatitis who require nutritional support.(GRADE 1B, strong agreement)
22. Either elemental or polymeric enteral nutrition formulations can be used in acute pancreatitis.(GRADE 2B, strong agreement)
23. Enteral nutrition in acute pancreatitis can be administered via either the nasojejunal or nasogastric route.(GRADE 2A, strong agreement)
24. Parenteral nutrition can be administered in acute pancreatitis as second-line therapy if nasojejunal tube feeding is not tolerated and nutritional support is
required.(GRADE 2C, strong agreement)
H. Biliary tract management
25. ERCP is not indicated in predicted mild biliary pancreatitis without cholangitis.(GRADE 1A, strong agreement). ERCP is probably not indicated in predicted severe
biliary pancreatitis without cholangitis (GRADE 1B, strong agreement). ERCP is probably indicated in biliary pancreatitis with common bile duct obstruction (GRADE 1C,
strong agreement) ERCP is indicated in patients with biliary pancreatitis and cholangitis (GRADE 1B, strong agreement)
26. Urgent ERCP (<24 hrs) is required in patients with acute cholangitis. Currently, there is no evidence regarding the optimal timing of ERCP in patients with biliary
pancreatitis without cholangitis.(GRADE 2C, strong agreement)
27. MRCP and EUSmay prevent a proportion of ERCPs that would otherwise be performed for suspected common bile duct stones in patients with biliary pancreatitis who
do not have cholangitis, without inﬂuencing the clinical course. EUS is superior to MRCP in excluding the presence of small (<5mm) gallstones. MRCP is less invasive,
less operator-dependent and probably more widely available than EUS. Therefore, in clinical practice there is no clear superiority for either MRCP or EUS.(GRADE 2C,
strong agreement)
I. Indications for intervention in necrotizing pancreatitis
28. Common indications for intervention (either radiological, endoscopical or surgical) in necrotizing pancreatitis are: 1) Clinical suspicion of, or documented infected
necrotizing pancreatitis with clinical deterioration, preferably when the necrosis has become walled-off, 2) In the absence of documented infected necrotizing
pancreatitis, ongoing organ failure for several weeks after the onset of acute pancreatitis, preferably when the necrosis has become walled-off.(GRADE 1C, strong
agreement)
29. Routine percutaneous ﬁne needle aspiration of peripancreatic collections to detect bacteria is not indicated, because clinical signs (i.e. persistent fever, increasing
inﬂammatory markers) and imaging signs (i.e. gas in peripancreatic collections) are accurate predictors of infected necrosis in the majority of patients. Although the
diagnosis of infection can be conﬁrmed by ﬁne needle aspiration (FNA), there is a risk of false-negative results.(GRADE 1C, strong agreement)
30. Indications for intervention (either radiological, endoscopical or surgical) in sterile necrotizing pancreatitis are: 1) Ongoing gastric outlet, intestinal, or biliary
obstruction due to mass effect of walled-off necrosis (i.e. arbitrarily >4-8 weeks after onset of acute pancreatitis), 2) Persistent symptoms (e.g. pain, ‘persistent
unwellness’) in patients with walled-off necrosis without signs of infection (i.e. arbitrarily >8 weeks after onset of acute pancreatitis), 3) Disconnected duct syndrome
(i.e. full transection of the pancreatic duct in the presence of pancreatic necrosis) with persisting symptomatic (e.g. pain, obstruction) collection(s) with necrosis without
signs of infections (i.e. arbitrarily >8 weeks after onset of acute pancreatitis).(GRADE 2C, strong agreement)
J. Timing of intervention in necrotizing pancreatitis
31. For patients with proven or suspected infected necrotizing pancreatitis, invasive intervention (i.e. percutaneous catheter drainage, endoscopic transluminal drainage/
necrosectomy, minimally invasive or open necrosectomy) should be delayed where possible until at least 4 weeks after initial presentation to allow the collection to
become ‘walled-off’.(GRADE 1C, strong agreement)
32. The best available evidence suggests that surgical necrosectomy should ideally be delayed until collections have becomewalled-off, typically 4 weeks after the onset of
pancreatitis, in all patients with complications of necrosis. No subgroups have been identiﬁed that might beneﬁt from earlier or delayed intervention.(GRADE 1C, strong
agreement)
K. Intervention strategies in necrotizing pancreatitis
33. The optimal interventional strategy for patients with suspected or conﬁrmed infected necrotizing pancreatitis is initial image-guided percutaneous (retroperitoneal)
catheter drainage or endoscopic transluminal drainage, followed, if necessary, by endoscopic or surgical necrosectomy.(GRADE 1A, strong agreement)
34. Percutaneous catheter or endoscopic transmural drainage should be the ﬁrst step in the treatment of patients with suspected or conﬁrmed (walled-off) infected
necrotizing pancreatitis.(GRADE 1A, strong agreement)
35. There are insufﬁcient data to deﬁne subgroups of patients with suspected or conﬁrmed infected necrotizing pancreatitis who would beneﬁt from a different treatment
strategy.(GRADE 2C, strong agreement)
L. Timing of cholecystectomy (or endoscopic sphincterotomy)
36. Cholecystectomy during index admission for mild biliary pancreatitis appears safe and is recommended. Interval cholecystectomy after mild biliary pancreatitis is
associated with a substantial risk of readmission for recurrent biliary events, especially recurrent biliary pancreatitis.(GRADE 1C, strong agreement)
37. Cholecystectomy should be delayed in patients with peripancreatic collections until the collections either resolve or if they persist beyond 6 weeks, at which time
cholecystectomy can be performed safely.(GRADE 2C, strong agreement)
38. In patients with biliary pancreatitis who have undergone sphincterotomy and are ﬁt for surgery, cholecystectomy is advised, because ERCP and sphincterotomy
prevent recurrence of biliary pancreatitis but not gallstone related gallbladder disease, i.e. biliary colic and cholecystitis.(GRADE 2B, strong agreement)
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Q1. What is the deﬁnition of acute pancreatitis (regardless of
etiology)?
The deﬁnition of acute pancreatitis is based on the fulﬁllment of
‘2 out of 3’ of the following criteria: clinical (upper abdominal
pain), laboratory (serum amylase or lipase >3 upper limit of
normal) and/or imaging (computed tomography, magnetic
resonance (MR), ultrasonography) criteria.(GRADE 1B, strong agreement)
Remarks: imaging studies (e.g. contrast-enhanced abdominal CT
abdomen (CT)) may be useful but are usually not required to
diagnose acute pancreatitis. Scenarios where cross-sectional im-
aging may be required to conﬁrm the diagnosis include sedated
patients, clinical suspicion of duodenal perforation, or a pro-
longed period between onset of symptoms and presentation
(lipase and amylase may have normalized). Although the urinary
trypsinogen-2 dipstick test is a rapid and non-invasive bedside
Working Group IAP/APA Acute Pancreatitis Guidelines / Pancreatology 13 (2013) e1ee15 e5test with adequate accuracy conﬁrmed in a recent meta-analysis
(pooled sensitivity 82% and speciﬁcity 94%), it was not included
because of its presumed limited availability [9].
Q2. On admission, what should be done to determine the
etiology of acute pancreatitis?
On admission, the etiology of acute pancreatitis should be
determined using detailed personal (i.e. previous acute
pancreatitis, known gallstone disease, alcohol intake, medica-
tion and drug intake, known hyperlipidemia, trauma, recent
invasive procedures such as endoscopic retrograde chol-
angiopancreatography (ERCP)) and family history of pancreatic
disease, physical examination, laboratory serum tests (i.e. liver
enzymes, calcium, triglycerides), and imaging (i.e. right upper
quadrant ultrasonography).
(GRADE 1B, strong agreement)
Remarks: as treatment and follow-up depend on the etiology of
pancreatitis (e.g. cholecystectomy for biliary pancreatitis and
dedicated follow-up visits after alcoholic pancreatitis to prevent
recurrence [10]) transabdominal ultrasonography should be
performed on admission. Although several studies have
demonstrated that a single biochemical parameter cannot be
recommended for reliable prediction of biliary etiology, it
should be noted that an alanine aminotransferase (ALT) level
>150 U/L within 48 h after onset of symptoms discriminates
biliary pancreatitis with a positive predictive value exceeding
85% [11e13].
Q3. What further investigations are indicated in patients
after a ﬁrst or second attack of idiopathic acute pancreatitis?
In patients considered to have idiopathic acute pancreatitis, af-
ter negative routine work-up for biliary etiology (e.g. repeated
right upper quadrant ultrasonography), endoscopic ultraso-
nography (EUS) is recommended as the ﬁrst step to assess for
occult microlithiasis, neoplasms and chronic pancreatitis. If EUS
is negative, (secretin-stimulated) magnetic resonance chol-
angiopancreatography (MRCP) is advised as a second step to
identify rare morphologic abnormalities. CT of the abdomen
should be performed (i.e. if not performed before). If etiology
remains unidentiﬁed, especially after a second attack of idio-
pathic pancreatitis, genetic counseling (not necessarily genetic
testing) should be considered.
(GRADE 2C, weak agreement)
Remarks: a systematic review of 5 studies including 416 patients
with idiopathic acute pancreatitis, reported a 32e88% diag-
nostic yield of EUS, detecting either biliary sludge or signs of
chronic pancreatitis [14]. If etiology remains unidentiﬁed after
EUS, thorough review and, if necessary, repeat (e.g. repeat lipid
proﬁle and calcium levels) or further investigations for other
more uncommon causes should be performed, depending on
the clinical scenario. It is recognized that several diagnostic tests
are not widely available and need speciﬁc expertise (e.g.
secretin-stimulated MRCP, genetic counseling, ERCP with
manometry, bile analysis). Their exact role in the diagnostic
algorithm has yet to be determined.
3.2. Prognostication/prediction of severity
Q4.What is the best score/marker (including cut-off value) to
predict severe acute pancreatitis on admission and at 48 h?
Systemic inﬂammatory response syndrome (SIRS) is advised to
predict severe acute pancreatitis at admission and persistent
SIRS at 48 h.
(GRADE 2B, weak agreement)
Remarks: a prediction of the course and outcome of the disease
on admission, although difﬁcult, can help with tailoring obser-
vations and initial treatment, using evidence from RCTs whichtypically select patients based on the predicted severity of acute
pancreatitis.
SIRS isdeﬁnedby thepresenceof twoormoreof the following four
criteria: (1) temperature< 36 C (96.8 F) or>38 C (100.4 F), (2)
heart rate >90/min, (3) respiratory rate >20/min, and (4) white
bloodcells (<4109/L (<4K/mm3),>12109(>12K/mm3)or10%
bands [15].
Persistent (>48 h) SIRS is associated with multi-organ failure
and mortality in acute pancreatitis. Persistent (>48 h) organ
failure is the key determinant of mortality in acute pancreatitis
[16]. Persistent SIRS was associated with a mortality of 25%
compared with 8% for transient SIRS [17]. The sensitivity of
persistent SIRS for mortality is 77e89% and speciﬁcity 79e86%
[17e19] and of SIRS at admission respectively 100% and 31% [18].
Arguments to recommend (persistent) SIRS as a marker for
predicting severe acute pancreatitis over the other predictive
scoring systems were highly pragmatic, taking into account the
widespread familiarity, simplicity, and the possibility for re-
petitive measurements [17,19]. It is recognized that there are
many different predictive scoring systems for acute pancreatitis
(e.g. APACHEII, Ranson and modiﬁed Glasgow score), including
single serum markers (C-reactive protein, hematocrit, procalci-
tonin, blood urea nitrogen), but none of these are clearly supe-
rior or inferior to (persistent) SIRS [20].
Q5. What is the best strategy to predict outcome of acute
pancreatitis during admission?
During admission, a 3-dimension approach is advised to predict
outcome of acute pancreatitis combining
 host risk factors (e.g. age, co-morbidity, bodymass index [21])
 clinical risk stratiﬁcation (e.g. persistent SIRS)
 monitoring response to initial therapy (e.g. persistent SIRS,
blood urea nitrogen [22], creatinine)
(GRADE 2B, strong agreement).
Remarks: this clinical approach links prognosis to patient’s
characteristics and response to initial treatment (e.g. ﬂuid
resuscitation) and places emphasis on reassessment to guide
further management [23]. More accurate prognostication could
facilitate a more tailored approach to treatment of individual
patients.
3.3. Imaging
Q6. What is the indication for and timing of the initial CT
assessment in acute pancreatitis?
The indication for initial CT assessment in acute pancreatitis can
be: (1) diagnostic uncertainty, (2) conﬁrmation of severity based
on clinical predictors of severe acute pancreatitis, or (3) failure
to respond to conservative treatment or in the setting of clinical
deterioration. Optimal timing for initial CT assessment is at least
72e96 h after onset of symptoms.
(GRADE 1C, strong agreement).
Remarks: in the majority of patients, CT is not required for the
diagnosis of acute pancreatitis. Routine early CT in acute
pancreatitis is not recommended for the following reasons: (1)
there is no evidence that early CT improves clinical outcome or
that early detection of necrosis will inﬂuence treatment; (2) CT
scoring systems are not superior to clinical scoring systems in
predicting prognosis and severity of disease [24]; (3) there is
evidence to suggest that an early (inappropriate) CT may in-
crease the duration of hospital stay [25], has low yield without
direct management implications [26], does not improve clinical
outcomes [27], and poses risks of contrast allergy and nephro-
toxicity. Because the complete extent of pancreatic and peri-
pancreatic necrosis may only become obvious 72 h after onset of
acute pancreatitis, a CT to assess the severity of pancreatitis
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formed only thereafter. Early CT may be useful to rule out bowel
ischemia or intra-abdominal perforations in patients presenting
with both acute pancreatitis and acute abdomen.
Q7. What is the indication for follow-up scanning (CT/MR)?
Follow-up CTorMR in acute pancreatitis is indicatedwhen there
is a lack of clinical improvement, clinical deterioration, or
especially when invasive intervention is considered.
(GRADE 1C, strong agreement).
Remarks: although routine follow-up CT (e.g. weekly) in acute
pancreatitis is advocated in several guidelines, evidence for this
practice is lacking. The present guidelines does not recommend
routine CT for initial assessment, because the vast majority of
complications can be suspected by clinical and biochemical
assessment. One important complication, namely arterial pseu-
doaneurysm formation, may not become clinically evident until
bleeding occurs, but this complication of acute pancreatitis is so
rare that it does not justify a ‘routine’ follow-up CT. MR may be
required to distinguish between pseudocysts and walled-off ne-
crosis as deﬁned by the revised Atlanta classiﬁcation at least 4
weeksafter the indexepisodeof acutepancreatitis. CT is frequently
not able to detect necrosis in a ﬂuid-predominant collection [29].
Q8. What is the optimal CT and MR protocol to detect
necrosis?
It is recommended to perform multidetector CT with thin
collimation and slice thickness (i.e. 5 mm or less), 100e150ml of
non-ionic intravenous contrast material at a rate of 3 ml/s,
during the pancreatic and/or portal venous phase (i.e. 50e70 s
delay). During follow-up only a portal venous phase (mono-
phasic) is generally sufﬁcient.
For MR, the recommendation is to perform axial FS-T2 and FS-T1
scanning before and after intravenous gadolinium contrast
administration.
(GRADE 1C, strong agreement).
Remarks: there is a wide variation in the literature regarding
CT and MR protocols but there are no existing dedicated
radiological guidelines. For CT, both the pancreatic and portal
venous phase are sufﬁcient for discriminating viable from
non-viable pancreatic tissue. The following indications would
require a multiphasic protocol: hemorrhage, arterial pseu-
doaneurysm and mesenteric infarction. An MR with T2-
weighted images is advised when the differentiation be-
tween pseudocysts and collections with necrosis (i.e. acute
necrotic collection and walled-off necrosis) is clinically rele-
vant and in young patients because of the radiation burden of
CT. Contrast-enhanced CT is clearly preferable, although in
patients with impending renal failure an initial non-contrast
CT is an option.
3.4. Fluid therapy
Q9. What is the best ﬂuid to use for initial ﬂuid resuscitation
in acute pancreatitis?
Ringer’s lactate is recommended for initial ﬂuid resuscitation in
acute pancreatitis.
(GRADE 1B, strong agreement).
Remarks: only very few studies have investigated the effect of
different ﬂuid types on outcome of acute pancreatitis [29e31].
In a multicenter RCT in 40 patients with acute pancreatitis,
resuscitation with Ringer’s lactate decreased the incidence of
SIRS when compared to resuscitation with normal saline [30].
The use of hydroxyethyl starch (HES) is discouraged since it
increased the rates of renal failure and mortality, as compared
to Ringer’s lactate in a multicenter RCT in patients with severe
sepsis in an intensive care [32]. Ringer’s lactate is very similarbut not identical to Hartmann’s solution. While there
is emerging evidence that addition of HES to ﬂuid resuscita-
tion in acute pancreatitis may be beneﬁcial [31], its detri-
mental effects in severe sepsis provide enough caution at this
stage that its use cannot be endorsed in the current
guidelines.
Q10. What is the optimal ﬂuid infusion rate and response
measurement for initial ﬂuid resuscitation?
Q10a. Optimal infusion rate for initial ﬂuid resuscitation: goal
directed intravenousﬂuidtherapywith5e10ml/kg/hshouldbe
used initially until resuscitation goals (see Q10b) are reached.
(GRADE 1B, weak agreement).
Remarks: in most patients, a total infusion of 2500e4000 ml
will sufﬁce to reach the resuscitation goals within the ﬁrst
24 h. There is moderate quality evidence from two RCTs, from
the same research group, that overly aggressive ﬂuid therapy
increases morbidity and mortality. In the ﬁrst RCT, patients
assigned to a ﬂuid infusion rate of 5e10 ml/kg/h experienced
less need for mechanic ventilation, abdominal compartment
syndrome, sepsis and mortality as compared to patients
assigned to 10e15 ml/kg/h infusion rates [33]. In a second
RCT, patients assigned to slow hemodilution, aiming at a
hematocrit >35% within 48 h, had decreased rates of sepsis
and mortality as compared to patients assigned to rapid
hemodilution, aiming at a hematocrit <35% within 48 h [34].
Because age and comorbidities such as heart failure need an
individualization of the ﬂuid management, the rate of in-
fusions suggested in these guidelines must be interpreted
with caution and needs to be tailored to the condition of the
patient.
Q10b.Measuring the response toﬂuid resuscitation: thepreferred
approachtoassessingthe responsetoﬂuid resuscitationshould
be based on one or more of the following: (1) non-invasive
clinical targets of heart rate <120/min, mean arterial pressure
between 65 and 85 mmHg (8.7e11.3 kPa), and urinary output
>0.5e1 ml/kg/h, (2) invasive clinical targets of stroke volume
variation, and intrathoracic blood volume determination, and
(3) biochemical targets of hematocrit 35e44%.
(GRADE 2B, weak agreement).
Remarks: non-invasive targets are useful on a regular ward,
while invasive targets are more appropriate in the intensive
care unit. It is unlikely that a single parameter will be as
reliable as the assessment of multiple parameters. Recent
studies have focused on blood urea nitrogen as a predictor of
outcome but not on its value as a responsemeasurement [22].
For biochemical parameters (e.g. hematocrit, blood urea ni-
trogen) not only the absolute level, but also the trend should
be noted. A recent study pointed out that central venous
pressure alone may be unreliable as a crude indicator of
adequate resuscitation [35].
3.5. Intensive care management
Q11. What are the indications for admission to an intensive
care unit in acute pancreatitis?
A patient diagnosed with acute pancreatitis and one or more of
the following parameters identiﬁed at admission as deﬁned by
the guidelines of the Society of Critical Care Medicine (SCCM)
[36] should be transferred immediately to an intensive care
setting: (1) pulse <40 or >150 beats/min; (2) systolic arterial
pressure <80 mmHg (<10.7 kPa) or mean arterial pressure
<60mmHg (<8.0 kPa) or diastolic arterial pressure>120mmHg
(>16 kPa); (3) respiratory rate >35 breaths/min; (4) serum so-
dium <110 mmol/l or >170 mmol/l; (5) serum potassium
<2.0 mmol/l or >7.0 mmol/l; (6) paO2 <50 mmHg (<6.7 kPa);
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(>44.4 mmol/L); (9) serum calcium> 15mg/dl (>3.75 mmol/L);
(10) anuria, or (11) coma. Furthermore, a patient with severe
acute pancreatitis as deﬁned by the revised Atlanta Classiﬁca-
tion (i.e. persistent organ failure) [6] should be treated in an
intensive care setting.
(GRADE 1C, strong agreement).
Remarks: every patient considered at high risk of rapid clinical
deterioration, such as those with persistent SIRS, the elderly,
the obese, patients requiring ongoing volume resuscitation,
and patients with moderately severe acute pancreatitis as
deﬁned by the revised Atlanta classiﬁcation [6] should be
assessed for admission to a high dependency unit (i.e. inter-
mediate care unit, level 2), if available. The routine use of
single markers, such as CRP, hematocrit, BUN or procalcitonin
alone to triage patients to an intensive care setting is not
recommended.
Q12. What are the indications for referral to a specialist
center?
Management in, or referral to, a specialist center is necessary
for patients with severe acute pancreatitis and for thosewhomay
need interventional radiologic, endoscopic, or surgical
intervention.
(GRADE 1C, strong agreement).
Remarks: a recent analysis of the United States Nationwide
Inpatient Sample suggested that treatment of patients with
acute pancreatitis in high volume centers (upper third, >118
patients per year) resulted in a decreased risk of prolonged
hospital stay and mortality (adjusted hazard ratio 0.74) [37].
Q13. What are the minimal requirements for a specialist
center?
A specialist center in the management of acute pancreatitis is
deﬁned as a high volume center with up-to-date intensive
care facilities including options for organ replacement ther-
apy, and with daily (i.e. 7 days per week) access to interven-
tional radiology, interventional endoscopy with EUS and ERCP
assistance as well as surgical expertise in managing necro-
tizing pancreatitis. Patients should be enrolled in prospective
audits for quality control issues and into clinical trials when-
ever possible.
(GRADE 2C, weak agreement).
Remarks: as there are no studies comparing requirements for
specialist centers, this recommendation can only be weak. As
optimal treatment of severe acute pancreatitis is achieved by a
multidisciplinary team, high volume academic centers usually
classify as specialist centers. A minimum of two specialists
should be available in all ﬁelds of expertise (interventional
radiology, interventional endoscopy, surgery, critical care med-
icine) to allow for minimum coverage.
Q14. Can persistent SIRS/organ failure be prevented?
Early ﬂuid resuscitation within the ﬁrst 24 h of admission for
acute pancreatitis is associated with decreased rates of persis-
tent SIRS and organ failure.
(GRADE 1C, strong agreement).
Remarks: persistent organ failure is the key determinant of
mortality in acute pancreatitis. Persistent SIRS resulted in a
mortality of 25% compared to 8% with transient SIRS [17,38].
Renal failure predicts mortality in severe acute pancreatitis.
Fluid resuscitation cannot prevent necrosis formation, but early
ﬂuid resuscitation is associated with reduced SIRS, organ fail-
ure and in-hospital mortality [39]. Enteral nutrition, as
compared to parenteral nutrition, decreases infectious com-
plications, organ failure and mortality [40,41]. The literature is
unclear on the impact of early feeding on early SIRS/organ
failure [42].Q15. What is the deﬁnition of abdominal compartment
syndrome?
Intra-abdominal pressure is the steady-state pressure within the
abdominal cavity. Abdominal compartment syndrome (ACS) is
deﬁned as a sustained intra-abdominal pressure > 20 mmHg
(with or without abdominal arterial perfusion pressure <
60 mmHg) that is associated with new onset organ failure.
(GRADE 2B, strong agreement).
Remarks: ACS cannot be diagnosed by physical examination and
requires objectivemeasurements of intra-abdominal pressure via
the bladder with a maximal instillation volume of 25ml of sterile
saline, as described in a 2013 international guideline [43]. Mea-
surement of intra-abdominal pressure should be considered in
mechanically ventilated patients with severe acute pancreatitis,
especially in case of clinical deterioration.
Intra-abdominal hypertension (IAH) is deﬁned by an ongoing or
repeated pathologic increase in intra-abdominal pressure
>12 mmHg. IAH is reported to occur in 60e80% of patients with
severe acute pancreatitis, but only a subset of these patients de-
velops ACS [44]. IAH is gradedas follows: grade I: intra-abdominal
pressure 12e15 mmHg; grade II 16e20 mmHg; grade III 21e
25mmHg; andgrade IV>25mmHg. Ina small, prospective cohort
study, IAH and ACS in patients with severe acute pancreatitis
contributed to gut barrier failure with signiﬁcantly greater endo-
toxin levels [45].
Q16. How should ACS be treated?
Medical interventions for ACS in acute pancreatitis: interventions
to decrease intra-abdominal pressure should target the most
important contributors to IAH in acute pancreatitis:
1) Hollow-viscera volume: nasogastric drainage, prokinetics,
rectal tubes, if necessary endoscopic decompression.
2) Intra/extra vascular ﬂuid: volume resuscitation on demand,
if volume overloaded either ultraﬁltration or diuretics can be
employed.
3) Abdominal wall expansion: adequate analgesia and sedation
to decrease abdominal muscle tone, if necessary neuro-
muscular blockade.
Invasive treatment for ACS in acute pancreatitis: invasive decom-
pression should only be used after multidisciplinary discussion in
patients with a sustained intra-abdominal pressure >25 mmHg
with new onset organ failure refractory to medical therapy and
nasogastric/rectal decompression. Invasive treatment options
include percutaneous catheter drainage of ascites, midline lapa-
rostomy, bilateral subcostal laparostomy, or subcutaneous linea
alba fasciotomy. In case of surgical decompression, the retroperi-
toneal cavity and the omental bursa should be left intact to reduce
the risk of infecting peripancreatic and pancreatic necrosis.
(GRADE 2C, strong agreement).
Remarks: although the necessity of decompression of ACS is a
rare event in severe acute pancreatitis, it may be lifesaving
[46]. RCTs comparing surgical decompression of ACS to other
treatment strategies are lacking. A 2013 international guide-
line discusses both the prevalence and etiologic factors for ACS
in various conditions, including acute pancreatitis, and pro-
vides an evidence-based approach to both diagnosis and
clinical management [43]. These guidelines state that because
of the obvious disadvantages of laparostomy/open abdomen,
percutaneous catheter drainage should be considered in pa-
tients with ACS and abundant abdominal ﬂuid on CT. Percu-
taneous drainage should lead to immediate and sustained
improvement, if not, surgical decompression should be per-
formed. To avoid an open abdomen and its negative effects of
evisceration of intestines, ﬂuid losses and contamination, a
primary closure with Mesh-grafts can be considered after open
laparotomy.
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Q17. Is systemic antibiotic prophylaxis effective in preventing
infectious complications in acute pancreatitis?
Intravenous antibiotic prophylaxis is not recommended for the
prevention of infectious complications in acute pancreatitis.
(GRADE 1B, strong agreement).
Remarks: according to a recent meta-analysis of 14 RCTs, there is
no evidence to support the routine use of antibiotic prophylaxis
in patients with (predicted) severe acute pancreatitis [47]. Ef-
fects of antibiotics may vary between subgroups, but more ev-
idence is needed [48]. A recent Cochrane meta-analysis
suggested a reduction in pancreatic infection in the subgroup of
patients who received imipenem, but the authors concluded
that more evidence is needed [49]. Prophylactic continuous
regional arterial infusion of antibiotics appears to be somewhat
promising but further studies are warranted [50]. Intravenous
antibiotics should be given in case of suspected infection of
necrotizing pancreatitis and further intervention considered
[50].
Q18. Is selective gut decontamination effective in preventing
infectious complications?
Selective gut decontamination has shown some beneﬁts in
preventing infectious complications in acute pancreatitis, but
further studies are needed.
(GRADE 2B, weak agreement).
Remarks: evidence on selective decontamination in acute
pancreatitis is limited to one RCT [51]. The results of this trial
have to be interpreted with caution, because it also included
non-randomized systemic antibiotic treatment.
Q19. Are probiotics effective in preventing infectious
complications?
Probiotic prophylaxis is not recommended for the prevention of
infectious complications in acute pancreatitis.
(GRADE 1B, strong agreement).
Remarks: there are abundant variations in type and dosage of
probiotic preparations. In one RCT in patients with predicted
severe acute pancreatitis a particular combination of probiotic
strains (i.e. Ecologic 641) did not prevent infectious compli-
cations but increased mortality [52].
3.7. Nutritional support
Q20. When should oral feeding be restarted in patients with
predicted mild pancreatitis?
Oral feeding in predicted mild pancreatitis can be restarted once
abdominal pain is decreasing and inﬂammatory markers are
improving.
(GRADE 2B, strong agreement).
Remark: it is not necessary to wait until pain or laboratory ab-
normalities completely resolve before restarting oral feeding.
One RCT showed that immediate oral refeeding with a normal
diet is safe in predicted mild pancreatitis and leads to a shorter
hospital stay (4 vs 6 days) [53]. A second RCT demonstrated that
feeding can be started with a full solid diet without a need to
ﬁrst start with a liquid or soft diet [54]. A third RCT showed that
there is no need to wait for normalization of lipase levels before
restarting oral feeding [55].
Q21. What is the indication for enteral tube feeding?
Enteral tube feeding should be the primary therapy in patients
with predicted severe acute pancreatitis who require nutritional
support.
(GRADE 1B, strong agreement).
Remarks: two meta-analyses demonstrated that enteral nutri-
tion, as compared with parenteral nutrition, decreases systemicinfections, multi-organ failure, need for surgical intervention,
and mortality [40,41]. The overwhelming majority of studies
were performed in patients with predicted severe acute
pancreatitis. Patients who can eat do not require additional
enteral nutrition via a feeding tube. A recent RCT in 60 patients
with ‘severe acute pancreatitis’ found improved outcomes when
enteral nutrition was started within 48 h as compared to after 7
days of fasting [56].
Q22. What type of enteral nutrition should be used?
Either elemental or polymeric enteral nutrition formulations
can be used in acute pancreatitis.
(GRADE 2B, strong agreement).
Remarks: a recent meta-analysis including 20 RCTs concluded
that there is no speciﬁc type of enteral nutrition or immuno-
nutrition that improves outcome in acute pancreatitis [57]. The
relatively inexpensive polymeric feeding formulations were
associated with similar feeding tolerance and appeared as
beneﬁcial as the more expensive (semi)elemental formulations
in reducing the risks of infectious complications and mortality.
Q23. Should enteral nutrition be administered via a nasoje-
junal or nasogastric route?
Enteral nutrition in acute pancreatitis can be administered via
either the nasojejunal or nasogastric route.
(GRADE 2A, strong agreement).
Remarks: two relatively small RCTs have suggested that naso-
gastric tube feeding is feasible and safe [58,59]. Although
nasogastric tube feeding is probably easier than nasojejunal
tube feeding, a number of patients will not tolerate nasogastric
feeding because of delayed gastric emptying.
Q24. What is the role of parenteral nutrition?
Parenteral nutrition can be administered in acute pancreatitis as
second-line therapy if nasojejunal tube feeding is not tolerated
and nutritional support is required.
(GRADE 2C, strong agreement).
Remarks: parenteral nutrition should only be started if the nutri-
tional goals cannot be reachedwithoral orenteral feeding [40,60].
A delay up to 5 days in initiation of parenteral nutrition may be
appropriate to allow for restarting of oral or enteral feeding.3.8. Biliary tract management
Q25. What is the indication for ERCP and sphincterotomy
early in the course of biliary pancreatitis?
 ERCP is not indicated in predicted mild biliary pancreatitis
without cholangitis(GRADE 1A, strong agreement).
 ERCP is probably not indicated in predicted severe
biliary pancreatitis without cholangitis (GRADE 1B, strong
agreement).
 ERCP is probably indicated in biliary pancreatitis with
common bile duct obstruction.
(GRADE 1C, strong agreement).
 ERCP is indicated in patients with biliary pancreatitis and
cholangitis (GRADE 1B, strong agreement).
Remarks: a recent meta-analysis of 7 RCTs including 757 patients
found no evidence that early routine ERCP signiﬁcantly affects
mortality or local/systemic complications, regardless of the
predicted severity of biliary pancreatitis [61]. The meta-analysis
did support ERCP in patients with cholangitis or co-existing
biliary obstruction. It should be noted that predicting the pres-
ence of CBD stones in the early stages of biliary pancreatitis with
laboratory ﬁndings, transabdominal ultrasonography or CT is
unreliable [62]. The individual trials, and even the pooled data in
the meta-analyses, did not include enough patients with ‘pre-
dicted severe biliary pancreatitis without cholangitis’ to study
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Q26. If indicated, what is the optimal timing for ERCP in
biliary pancreatitis?
Urgent ERCP (<24 h) is required inpatientswith acute cholangitis.
Currently, there is no evidence regarding the optimal timing of
ERCP in patients with biliary pancreatitis without cholangitis.
(GRADE 2C, strong agreement).
Remarks: the recent meta-analysis found no statistically signif-
icant effect of the timing of ERCP (<24 vs. <72 h) on mortality
[61]. However, no studies were speciﬁcally designed to study
timing of ERCP in biliary pancreatitis. Because it is unclear what
the exact timing of early ERCP should be (24e72 h), it is
reasonable to await spontaneous improvement of biliary
obstruction for 24e48 h. It is important, that ERCP is performed
as soon as possible in patients with cholangitis.
Q27.What is the role of MRCP and EUS in biliary pancreatitis?
MRCP and EUS may prevent a proportion of ERCPs that would
otherwise be performed for suspected common bile duct
stones in patients with biliary pancreatitis who do not have
cholangitis, without inﬂuencing the clinical course. EUS is
superior to MRCP in excluding the presence of small (<5 mm)
gallstones. MRCP is less invasive, less operator-dependent and
probably more widely available than EUS. Therefore, in clin-
ical practice there is no clear superiority for either MRCP or
EUS.
(GRADE 2C, strong agreement).
Remarks: MRCP, EUS and ERCP are generally not indicated in
patients with mild biliary pancreatitis without clinical evidence
of persistent common bile duct obstruction, as that can be
treated with (early) cholecystectomy with/without intra-
operative cholangiography. One RCT found that EUS could safely
replace diagnostic ERCP in patients with biliary pancreatitis
[63]. It should be noted that access to urgent MRCP and EUS is
likely to be limited in most hospitals. A negative MRCP does not
exclude the presence of small (<5 mm) common bile duct
stones [64]. This is especially relevant because small stones are
known to cause biliary pancreatitis [65].3.9. Indications for intervention in necrotizing pancreatitis
Q28. What are the indications for intervention in necrotizing
pancreatitis?
Common indications for intervention (either radiological,
endoscopical or surgical) in necrotizing pancreatitis are:
 Clinical suspicion of, or documented, infected necrotizing
pancreatitis with clinical deterioration, preferably when the
necrosis has become walled-off.
 In the absence of documented infected necrotizing pancre-
atitis, ongoing organ failure for several weeks after the onset
of acute pancreatitis, preferably when the necrosis has
become walled-off.
Less common indications for intervention are:
 Abdominal compartment syndrome
 Ongoing acute bleeding
 Bowel ischemia
 Ongoing gastric outlet, intestinal, or biliary obstruction due to
mass effect from large walled-off necrosis (arbitrarily >4e8
weeks after onset of pancreatitis)
(GRADE 1C, strong agreement).
Remarks: the vast majority of patients with sterile necrotizing
pancreatitis can be managed without intervention (i.e. catheter
drainage or necrosectomy). Walled-off necrosis usually occurs
>4 weeks after onset of acute pancreatitis [6]. The presence ofgas in peripancreatic collections on CT is considered evidence of
infected necrotizing pancreatitis, irrespective of the source of
the gas (i.e. loss of integrity of the gastrointestinal tract or
through gas-forming bacteria). In patients who are operated on
because of ‘persistent unwellness’ (also known as ‘failure to
thrive’) approximately 40% will have infected necrotizing
pancreatitis [66]. A small proportion of patients with docu-
mented infected necrosis who remain clinically stable can be
managed with antibiotics alone, without the need for percuta-
neous catheter drainage or necrosectomy. Future studies should
compare (initial) antibiotic treatment of infected necrosis with
other, more invasive, strategies [67e70]. During surgical in-
terventions for ACS, acute bleeding, or bowel ischemia in sterile
necrotizing pancreatitis, drainage or necrosectomy is not indi-
cated because these procedures may increase the risk of
developing infected necrosis. Spontaneous ﬁstula formation
between the gastrointestinal tract and necrosis may occur in the
absence of documented bowel ischemia. In cases of clinical
suspicion, without evidence on imaging, bowel ischemia can be
diagnosed by colonoscopy or, if negative, laparoscopy. Finally,
very rare complications requiring (non-surgical) intervention
include pancreaticopleural ﬁstula, pancreatic ascites, obstruc-
tive jaundice due to the enlargement of the pancreatic head, and
ongoing symptoms (i.e. pain, gastric outlet obstruction) from a
‘true’ pseudocyst (i.e. conﬁrmed absence of necrosis in the
collection on MR or ultrasonography).
Q29. What is the role of ﬁne needle aspiration to diagnose
infected necrotizing pancreatitis?
Routine percutaneous ﬁne needle aspiration of peripancreatic
collections todetectbacteria isnot indicated,because clinical signs
(i.e. persistent fever, increasing inﬂammatory markers) and im-
aging signs (i.e. gas in peripancreatic collections) are accurate
predictorsof infectednecrosis in themajorityofpatients.Although
the diagnosis of infection can be conﬁrmed by ﬁne needle aspi-
ration (FNA), there is a risk of false-negative results [66].
(GRADE 1C, strong agreement).
Remarks: false-negative FNA results in patients with infected
necrotizing pancreatitis have been reported in 12e25% of pa-
tients [66,71]. FNA is indicated in patients without clinical
improvement for several weeks after onset of necrotizing
pancreatitis in the absence of clear clinical and imaging signs of
infected necrotizing pancreatitis. There is no evidence that the
theoretical beneﬁts of FNA, shortening the period to diagnosis of
infected necrosis and tailoring antibiotic treatment, improve
outcome.
Q30. What are the indications for intervention in sterile
necrotizing pancreatitis?
Indications for intervention (either radiological, endoscopical or
surgical) in sterile necrotizing pancreatitis are:
 Ongoing gastric outlet, intestinal, or biliary obstruction due
to mass effect of walled-off necrosis (i.e. arbitrarily >4e8
weeks after onset of acute pancreatitis).
 Persistent symptoms (e.g. pain, ‘persistent unwellness’) in
patients with walled-off necrosis without signs of infection
(i.e. arbitrarily >8 weeks after onset of acute pancreatitis).
 Disconnected duct syndrome (i.e. full transection of the
pancreatic duct in the presence of pancreatic necrosis) with
persisting symptomatic (e.g. pain, obstruction) collection(s)
with necrosis without signs of infections (i.e. arbitrarily >8
weeks after onset of acute pancreatitis).
(GRADE 2C, strong agreement).
Remarks: according to one observational study in 639 patients,
approximately 1% of patients with necrotizing pancreatitis will
have symptoms of obstruction during the initial hospital
admission necessitating intervention [67]. A recent study of
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found a disconnected duct syndrome in 40% of patients and
about half of these patients required an intervention more than
8 weeks after surviving necrotizing pancreatitis [72]. Further
data are needed on the indication, timing, and type of inter-
vention in the months after an episode of necrotizing pancre-
atitis. Rare complications requiring (non-surgical) intervention
in the follow-up after sterile necrotizing pancreatitis are pan-
creaticopleural ﬁstula, pancreatic ascites, and a ‘true’ (no ne-
crosis found in the collection on MR or ultrasonography)
symptomatic pseudocyst. Prospective cohort studies suggest
that patients with ‘persistent unwellness’ and necrotizing
pancreatitis should probably undergo intervention 6e8 weeks
after onset of the disease [66,73].
3.10. Timing of intervention in necrotizing pancreatitis
Q31.What is the optimal timing of intervention for suspected
or conﬁrmed infected necrosis?
For patients with proven or suspected infected necrotizing
pancreatitis, invasive intervention (i.e. percutaneous catheter
drainage, endoscopic transluminal drainage/necrosectomy,
minimally invasive or open necrosectomy) should be delayed
where possible until at least 4 weeks after initial presentation to
allow the collection to become ‘walled-off’.
(GRADE 1C, strong agreement).
Remarks: open necrosectomy is associated with poor outcomes
when performed early [67,73e76]. In a subset of patients it will
not be feasible to delay intervention until 4 weeks. Even if
initial percutaneous catheter drainage is undertaken early,
necrosectomy should ideally still be delayed until the collection
has become walled-off. The timing for repeat interventions (e.g.
repeat percutaneous drainage, repeat endoscopic necrosec-
tomy, or crossover to surgery) should be based on clinical and
imaging criteria, and no strict guidelines can be recommended.
Consultation with a specialist center before interventional
treatment is advisable.
Q32. Can subgroups of patients with necrotizing pancreatitis
be deﬁned that require early or late intervention?
The best available evidence suggests that surgical necrosectomy
should ideally be delayed until collections have become walled-
off, typically 4 weeks after the onset of pancreatitis, in all pa-
tients with complications of necrosis. No subgroups have been
identiﬁed that might beneﬁt from earlier or delayed intervention.
(GRADE 1C, strong agreement).
Remarks: regardless of the presence of necrosis, patients with
intra-abdominal catastrophes (hemorrhage, perforation,
abdominal compartment syndrome) require immediate
intervention. Minimally invasive methods to address these
problems such as angioembolization/-stenting or percuta-
neous catheter drainage of ascites should be considered in a
multidisciplinary team including at least interventional radi-
ologists, endoscopists, and surgeons. Loop ileostomy may be
considered for patients with a colonic ﬁstula secondary to
(infected) necrotizing pancreatitis, in the absence of bowel
ischemia.
3.11. Intervention strategies in necrotizing pancreatitis
Q33. What is the optimal interventional strategy (percuta-
neous catheter drainage, endoscopic transluminal drainage/
necrosectomy, minimally invasive or open necrosectomy) for
suspected or conﬁrmed infected necrotizing pancreatitis?
The optimal interventional strategy for patients with suspected
or conﬁrmed infected necrotizing pancreatitis is initial image-guided percutaneous (retroperitoneal) catheter drainage or
endoscopic transluminal drainage, followed, if necessary, by
endoscopic or surgical necrosectomy.
(GRADE 1A, strong agreement).
Remarks: a multicenter RCT in 88 patients with (suspected)
infected necrotizing pancreatitis showed that a step-up
approach of percutaneous (retroperitoneal) catheter
drainage, followed, if needed, by minimally invasive
necrosectomy decreased major short-term complications such
as new onset multi-organ failure and long-term complications
such as endocrine insufﬁciency, and decreased costs as
compared to primary open necrosectomy [77]. Left retroperi-
toneal catheter drainage can facilitate minimally invasive
retroperitoneal necrosectomy. If catheter drainage fails [78],
the optimal method of necrosectomy (i.e. minimally invasive
or open surgery or endoscopic transluminal) is unclear.
Minimally invasive necrosectomy may be associated with a
decreased risk of complications and death as compared to
open necrosectomy [79]. Several series from centers both in
Europe and in the US have conﬁrmed the efﬁcacy of endo-
scopic transluminal necrosectomy [80,81]. A pilot multicenter
RCT in 22 patients suggested that endoscopic transluminal
necrosectomy may be superior to surgical necrosectomy in
terms of risk of new onset multiple organ failure and overall
complications [82]. There is however a large variance in
expertise with the various techniques between centers which
has to be taken into account.
Q34. Should catheter drainage (percutaneous or endoscopic
transluminal) always be the ﬁrst step for suspected or
conﬁrmed infected necrotizing pancreatitis?
Percutaneous catheter or endoscopic transmural drainage should
be the ﬁrst step in the treatment of patients with suspected or
conﬁrmed (walled-off) infected necrotizing pancreatitis.
(GRADE 1A, strong agreement).
Remarks: percutaneous catheter drainage alone will prevent
23e50% of necrosectomies in patients with infected necrotizing
pancreatitis [75,77,78,83,84]. Percutaneous catheter drainage is
technically feasible in >95% of patients with infected necrosis
[77]. One prospective, observational multicenter study of 40
patients found that a decrease in the size of the collection of at
least 75% after the ﬁrst 10e14 days of percutaneous drainage
(n ¼ 9, 23%) correctly predicts successful percutaneous treat-
ment [75] but more data are needed to conﬁrm this ﬁnding.
After catheter drainage, it is imperative that the patient is fol-
lowed by an experienced clinician, who in the absence of clinical
improvement can direct the next appropriate therapeutic step
(i.e. surgical or endoscopic necrosectomy). Although the use of
larger bore drains are sometimes claimed to yield better results,
data are lacking. Overall, there is currently less experience with
endoscopic transluminal drainage than with percutaneous
drainage.
Q35. Can subgroups of patients with infected necrotizing
pancreatitis be deﬁned who require different strategies
(including conservative treatment)?
There are insufﬁcient data to deﬁne subgroups of patients with
suspected or conﬁrmed infected necrotizing pancreatitis who
would beneﬁt from a different treatment strategy.
(GRADE 2C, strong agreement).
Remarks: in a predeﬁned subgroup analysis on severity in a
multicenter RCT, the effect of the step-up approach was
beneﬁcial in patients with and without multiple organ failure
[77]. No other prospective studies were speciﬁcally designed
to assess the efﬁcacy of certain treatment strategies in speciﬁc
subgroups. Although several small cohort studies have
reported success of conservative treatment (i.e. antibiotics
Working Group IAP/APA Acute Pancreatitis Guidelines / Pancreatology 13 (2013) e1ee15 e11alone) for infected necrosis the exact subgroup in which this
strategy may be successful has not accurately been deﬁned.3.12. Timing of cholecystectomy (or endoscopic sphincterotomy)
Q36. What is the optimal timing of cholecystectomy after
mild biliary pancreatitis?
Cholecystectomy during index admission for mild biliary
pancreatitis appears safe and is recommended. Interval chole-
cystectomy after mild biliary pancreatitis is associated with a
substantial risk of readmission for recurrent biliary events,
especially recurrent biliary pancreatitis.
(GRADE 1C, strong agreement).
Remarks: a systematic review of nine studies including 998 pa-
tients found an 18% readmission rate for recurrent biliary events a
median of 6 weeks after index admission for mild biliary
pancreatitis [85]. Although cholecystectomy during index
admission appeared safe, selection bias could not be excluded
[85]. ERCP with sphincterotomy before cholecystectomy
decreased the rate of recurrent biliary pancreatitis but not of other
biliary events [86]. It should be noted that ERCP is rarely indicated
in mild biliary pancreatitis, except in the case of cholangitis (see
Q25). Alternatively, preoperative MRCP or EUS, or intraoperative
cholangiography can be performed during cholecystectomy to
select out those patients with common bile duct stones who
should be treated either by operative bile duct exploration or
endoscopic sphincterotomy. In unﬁt elderly (i.e. arbitrarily
>80 yrs) patients one could refrain from cholecystectomy, espe-
cially if sphincterotomywas already performed, althougha subset
of these patients will develop recurrent biliary colics [87].
Q37. What is the optimal timing of cholecystectomy after
severe biliary pancreatitis?
Cholecystectomy should be delayed in patients with peri-
pancreatic collections until the collections either resolve or if
they persist beyond 6weeks, at which time cholecystectomy can
be performed safely.
(GRADE 2C, strong agreement).
Remarks: one retrospective study of 151 patients found an
increased incidence of infected collections in patients who un-
derwent early cholecystectomy after severe pancreatitis [88]. A
second retrospective study of 30 patients reported no episodes of
recurrent biliary pancreatitis during the waiting period for inter-
val cholecystectomy after routine ERCP and sphincterotomy [89].
Q38. What is the role of cholecystectomy after endoscopic
sphincterotomy in biliary pancreatitis?
In patients with biliary pancreatitis who have undergone
sphincterotomy and are ﬁt for surgery, cholecystectomy is
advised, because ERCP and sphincterotomy prevent recurrence
of biliary pancreatitis but not gallstone related gallbladder dis-
ease, i.e. biliary colic and cholecystitis.
(GRADE 2B, strong agreement).
Remarks: one meta-analysis reported a 10% readmission rate
after ERCP for mild biliary pancreatitis because of biliary colic
and acute cholecystitis [85]. Studies on this topic in severe
biliary pancreatitis are lacking. In severe biliary pancreatitis,
cholecystectomy should be postponed for 6 weeks.4. Conclusion
The IAP/APA guidelines on the management of acute
pancreatitis are the result of an international, multidisciplinary,
evidence-based approach. These guidelines provide recommen-
dations to key aspects of medical and surgical management
of acute pancreatitis combined with remarks based on theavailable literature and the opinion of leading pancreatologists
worldwide.
Focus should now shift to optimal dissemination and imple-
mentation of these guidelines [90]. Several studies have indicated
that guideline implementation in acute pancreatitis is frequently
suboptimal [91e94] and hence a structured, ongoing effort is
required. Dissemination will be facilitated by free online access to
these guidelines. Although there is no optimal strategy to ensure
good implementation of a guideline [95], there is clearly a role for
pancreatologists in this process. By informing specialist and non-
specialist colleagues and encouraging them to use these guide-
lines, by presenting the guidelines in local or national meetings and
by writing about and referring to these guidelines in (inter-)na-
tional journals, pancreatologists can optimize implementation of
these guidelines. Some evidence also suggests that auditing could
increase awareness and improve guideline implementation [96].
These guidelineswill alsobeusefulwhendesigning future studies
as they reﬂect the current ‘benchmark’ of treating acute pancreatitis.
The existence of evidence-based guidelines obviously does not
relieve clinicians from the professional obligation to keep up-to-date
with new developments in acute pancreatitis. Especially, the results
of currently ongoing randomized controlled trials (http://apps.who.
int/trialsearch/) should be taking into account. How than to decide
when to update these guidelines? Some have argued that a clinical
guideline should beupdated continuously. Althoughappealing this is
clearly impractical. The Working group will use a published frame-
work on how to decide when to update these guidelines [8].
These guidelines on the management of acute pancreatitis
should result in reduced variation in practice and an improvement
in patient outcome. The challenge now is to ensure high compli-
ance in clinical practice and trial design.
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B ¼ moderate quality evidence.
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 High likelihood of publication bias.
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